Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded...
-
Preclinical data continues to demonstrate RECCE® 327’s significant bactericidal activity against Neisseria gonorrhoeae (N. gonorrhoeae), with a 4-log (99.99%) and 3.5-log (>99.9%) reductionN....
-
SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
-
Phase I/II study is tracking to meet primary endpointsRECCE® 327 at 3,000mg over 15 minutes marks the fastest infusion rate of a high concentrationCohort fully recruited with remaining subjects to be...
-
Independent Safety Committee approves the next cohort dosing of RECCE® 327 (R327) at a faster infusion rate of 15 minutes of 3,000mg via intravenous (IV) administrationR327 was shown to be safe and...
-
SYDNEY, Australia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), the Company developing a new class of synthetic anti-infectives, announced...
-
Cohort dosing complete in healthy subjects, with the Phase I/II study on track to meet primary endpointsRECCE® 327 was found to be safe and well-tolerated at a faster infusion rate of 30 minutes of...
-
$8 million commitments received in a strongly supported placement to new and existing institutional investors $3 million entitlement offer at the same offer price as the placementDirectors intend to...
-
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
-
RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under the Therapeutic Goods Administration (TGA) Special...